Get the Stockscreener App
6.195
4.40%
-0.285
After Hours:
6.10
-0.095
-1.53%
Harvard Bioscience Inc stock is traded at $6.195, with a volume of 8,874.
It is down -4.40% in the last 24 hours and down -6.56% over the past month.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
See More
Previous Close:
$6.48
Open:
$6.43
24h Volume:
8,874
Relative Volume:
0.17
Market Cap:
$27.94M
Revenue:
$86.55M
Net Income/Loss:
$-56.70M
P/E Ratio:
-2.4093
EPS:
-2.5713
Net Cash Flow:
$4.87M
1W Performance:
+5.36%
1M Performance:
-6.56%
6M Performance:
-18.24%
1Y Performance:
+50.00%
1-Day Range:
$6.01
$6.43
1-Week Range:
$5.76
$6.69
52-Week Range:
$3.71
$9.40
Harvard Bioscience Inc Stock (HBIO) Company Profile
Name
Harvard Bioscience Inc
Sector
Industry
Phone
(508) 893-8999
Address
84 OCTOBER HILL RD, HOLLISTON, MA
Compare HBIO vs ISRG, BDX, ALC, RMD, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HBIO
Harvard Bioscience Inc
|
6.195 | 29.23M | 86.55M | -56.70M | 4.87M | -2.5713 |
ISRG
Intuitive Surgical Inc
|
422.06 | 148.33B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
151.16 | 41.21B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
66.81 | 32.47B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
196.04 | 28.19B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
33.61 | 29.13B | 29.14B | 1.07B | 1.05B | 1.1956 |
Harvard Bioscience Inc Stock (HBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-25 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Mar-10-23 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Jan-07-21 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Dec-09-20 | Initiated | Northland Capital | Outperform |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jul-08-19 | Downgrade | Janney | Buy → Neutral |
| Jan-24-18 | Reiterated | Janney | Buy |
| Jan-23-18 | Reiterated | The Benchmark Company | Buy |
| Nov-17-16 | Initiated | Singular Research | Buy |
| Jul-28-15 | Initiated | The Benchmark Company | Buy |
View All
Harvard Bioscience Inc Stock (HBIO) Latest News
HBIO Stock Price, Quote & Chart | HARVARD BIOSCIENCE INC (NASDAQ:HBIO) - ChartMill
Harvard Bioscience | 8-K: Harvard Bioscience Announces First Quarter 2026 Financial Results - Moomoo
Harvard Bioscience Shareholders Expand Equity Plans, Elect Directors - TipRanks
Harvard Bioscience (NASDAQ: HBIO) shareholders approve equity and ESPP share increases - Stock Titan
Harvard Bioscience (HBIO) price target increased by 200.00% to 6.12 - MSN
Earnings call transcript: Harvard Bioscience Q1 2026 misses EPS forecast, stock drops - Investing.com Nigeria
Harvard Bioscience: HBIO stock stalls, margin pressure in focus - Bez Kabli
HBIO PE Ratio & Valuation, Is HBIO Overvalued - Intellectia AI
HBIO Q1 2026 Earnings: EPS Surprises to the Upside Despite Challenging QuarterEstimate Dispersion - thelegaladvocate.com
Harvard Bioscience Slips as Traders Assess Support Levels; HBIO Down Nearly 3%Open Trading Community - Newser
Harvard Bioscience (HBIO) Q1 2026 Earnings Beat: Revenue $N/A, EPS $-0.33Real Trader Insights - Newser
Harvard Bioscience stock (US4169061052): Q2 2025 mixed results still define the story - AD HOC NEWS
Harvard Bioscience, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:HBIO) 2026-05-15 - Seeking Alpha
Earnings call transcript: Harvard Bioscience misses Q1 2026 forecasts - Investing.com UK
Earnings call transcript: Harvard Bioscience misses Q1 2026 forecasts By Investing.com - Investing.com Australia
Harvard Bioscience (HBIO) insider entity reports 293,676 shares, 6.5% stake - Stock Titan
Harvard Bioscience Transitions to Translational Science Focus in 2026 - HarianBasis.co
Harvard Bioscience, Inc. (NASDAQ:HBIO) Q1 2026 Earnings Call Transcript - Insider Monkey
Harvard Bioscience Inc (HBIO) Q1 2026 Earnings Call Highlights: Revenue Growth Driven by New Product Innovations - GuruFocus
Harvard Bioscience Q1 2026 slides: margins rise amid revenue miss By Investing.com - Investing.com Nigeria
Harvard Bioscience Q1 2026 Earnings Call Transcript - MarketBeat
HBIO Maintains Positive Outlook for FY26 Financial Performance - GuruFocus
Harvard Bioscience (HBIO) Reports Q1 Earnings and Reaffirms 2026 Revenue Guidance - GuruFocus
Discontinued operations of Harvard Bioscience, Inc. – FWB:HBI0 - TradingView
Harvard Bioscience Reaffirms Full-Year 2026 Financial Guidance >HBIO - Moomoo
Harvard Bioscience: Consolidation of Manufacturing Operations Progressing on Schedule >HBIO - Moomoo
Harvard Bioscience (NASDAQ: HBIO) posts Q1 2026 loss as debt costs rise - Stock Titan
Harvard Bioscience, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
HBIO Forecasts Q2 Margins and Revenue Growth - GuruFocus
HBIO Sees Q1 Revenue at $20.8M, Positive Trends in Product Adoption - GuruFocus
Harvard Bioscience reaffirms 2026 outlook for 2%-4% revenue growth as Project Viking targets $4M annual savings - MSN
Harvard Bioscience Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Harvard Bioscience (HBIO) Q1: EPS Not Disclosed, Revenue $20.8M - GuruFocus
Harvard Bioscience Q1 2026 slides: margins rise amid revenue miss - Investing.com
Harvard Bioscience Still Sees 2026 Revenue Up 2%-4% >HBIO - Moomoo
Earnings call transcript: Harvard Bioscience Q1 2026 misses EPS forecast, stock drops By Investing.com - Investing.com South Africa
Harvard Bioscience Announces Q1 2026 Financial Results: $20.8M Revenue, 59% Gross Margin, Key SEC Filing Details 9 - Minichart
Harvard Bioscience Accelerates Growth with Human-Relevant Translational Tools, Leading Recurring Revenue and Innovation in Preclinical Research (May 2026) 10121415 - Minichart
Harvard Bioscience Still Sees 2026 Adjusted Ebitda Up 6%-10% >HBIO - Moomoo
Harvard Bioscience Inc (NASDAQ:HBIO) Q1 Results Show Revenue Miss Offsets Earnings Beat - ChartMill
HARVARD BIOSCIENCE ($HBIO) Releases Q1 2026 Earnings - Quiver Quantitative
Harvard Bioscience Announces First Quarter 2026 Financial Results - The Manila Times
Harvard Bioscience: Q1 Earnings Snapshot - marketscreener.com
Harvard Bioscience (NASDAQ: HBIO) details debt refinancing, FY26 outlook and $7M convertible loan - Stock Titan
Harvard Bioscience (NASDAQ: HBIO) Q1 2026 margin up as loss shrinks - Stock Titan
HBIO Q1 2026 Earnings Transcript - The Globe and Mail
Inventory turnover of Harvard Bioscience, Inc. – LS:A423J5 - TradingView
Harvard Bioscience Inc Stock (HBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Harvard Bioscience Inc Stock (HBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DENELSKY STEPHEN J | Director |
Mar 17 '26 |
Buy |
4.87 |
10,000 |
48,700 |
21,000 |
| Snider William | Director |
Mar 16 '26 |
Buy |
4.99 |
12,525 |
62,500 |
23,525 |
| Snider William | Director |
Mar 17 '26 |
Buy |
4.85 |
8,475 |
41,104 |
32,000 |
| Duke John D | Chief Executive Officer |
Mar 16 '26 |
Buy |
5.01 |
5,000 |
25,050 |
105,000 |
0.16%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):